Title :

Cytokines as prognostic biomarkers in pulmonary arterial hypertension

Author(s) :

Boucly, Athénaïs [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Tu, Ly [Auteur]
Centre Chirurgical Marie Lannelongue [CCML]
Hypertension arterielle pulmonaire physiopathologie et innovation thérapeutique [HPPIT]
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Guignabert, Christophe [Auteur]
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Rhodes, Christopher [Auteur]
Imperial College London
De Groote, Pascal [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Prévot, Grégoire [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Bergot, Emmanuel [Auteur]
Service de pneumologie [CHU Caen]
Bourdin, Arnaud [Auteur]
Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] [PhyMedExp]
Beurnier, Antoine [Auteur]
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Roche, Anne [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Jevnikar, Mitja [Auteur]
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Jaïs, Xavier [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Montani, David [Auteur]
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Wilkins, Martin [Auteur]
Humbert, Marc [Auteur]
Université Paris-Saclay
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Centre de Référence de l’Hypertension Pulmonaire Sévère [CHU Le Kremlin Bicêtre]
Sitbon, Olivier [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]
Savale, Laurent [Auteur]
Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay
Hypertension pulmonaire : physiopathologie et innovation thérapeutique [HPPIT]

Journal title :

European Respiratory Journal

Pages :

2201232

Publisher :

European Respiratory Society

Publication date :

2023-03-22

ISSN :

0903-1936

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background Risk stratification and assessment of disease progression in patients with pulmonary arterial hypertension (PAH) are challenged by the lack of accurate disease-specific and prognostic biomarkers. To date, brain ...
Show more >Background Risk stratification and assessment of disease progression in patients with pulmonary arterial hypertension (PAH) are challenged by the lack of accurate disease-specific and prognostic biomarkers. To date, brain natriuretic peptide (BNP) and/or its N-terminal fragment (NT-proBNP) are the only markers for right ventricular dysfunction used in clinical practice, in association with echocardiographic and invasive haemodynamic variables to predict outcome in patients with PAH. Methods This study was designed to identify an easily measurable biomarker panel in the serum of 80 well-phenotyped PAH patients with idiopathic, heritable or drug-induced PAH at baseline and at first follow-up. The prognostic value of identified cytokines of interest was secondly analysed in an external validation cohort of 125 PAH patients. Results Among the 20 biomarkers studied with the multiplex Ella platform, we identified a three-biomarker panel composed of β-NGF, CXCL9 and TRAIL that were independently associated with prognosis both at the time of PAH diagnosis and at the first follow-up after initiation of PAH therapy. β-NGF and CXCL9 were predictors of death or transplantation, whereas high levels of TRAIL were associated with a better prognosis. Furthermore, the prognostic value of the three cytokines was more powerful for predicting survival than usual non-invasive variables (New York Heart Association Functional Class, 6-min walk distance and BNP/NT-proBNP). The results were validated in a fully independent external validation cohort. Conclusion The monitoring of β-NGF, CXCL9 and TRAIL levels in serum should be considered in the management and treatment of patients with PAH to objectively guide therapeutic options.Show less >

Language :

Anglais

Popular science :

Non

Collections :

• Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167

Source :

Harvested from HAL